Testing SYX-5219 for atopic dermatitis in healthy people and patients
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–65 years old
- Your BMI (body mass measurement) must be under 32 kg/m² (Part 1 & 2) or under 40 kg/m² (Part 3)
- For Part 3 only: diagnosed with active atopic dermatitis covering at least 10% of your body with moderate to severe symptoms
- For Part 3 only: you must have significant itching (score of 4 or higher on a pain scale) at screening
- You cannot take prescription drugs, over-the-counter medications, vitamins, or herbal supplements for at least 35 days before the study starts
- You must have no serious medical conditions or abnormal blood tests, heart rhythm, or vital signs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.